Nabi Announces Plans To Evaluate Merger Or Sale Of Firm Under New CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
Company refocuses on primary compounds, smoking-cessation vaccine NicVAX and Staphylococcus aureus vaccine StaphVax.
You may also be interested in...
Infectious Opportunity? Nabi Biopharma Sells Staph A Vaccine To Glaxo For $46M
The sale will enable the little company to focus solely on its nicotine-addiction vaccine candidate, NicVAX.
Infectious Opportunity? Nabi Biopharma Sells Staph A Vaccine To Glaxo For $46M
The sale will enable the little company to focus solely on its nicotine-addiction vaccine candidate, NicVAX.
Pfizer’s Loss Could Be Nabi’s Gain In Stop-Smoking Space
Phase II vaccine, unlike Chantix, does not cross blood-brain barrier.